For the year ending 2025-12-31, CB had -$79M decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net realized gains (losses) | - | - | -607 | -965 |
| Interest expense | - | - | - | 570 |
| Market risk benefits gains (losses) | - | - | -307 | - |
| Cigna integration expenses | - | - | 69 | 48 |
| Income tax expense | - | - | 511 | 1,255 |
| Net investment income | - | - | 4,937 | 3,742 |
| Other (income) expense | - | - | 836 | -74 |
| Amortization of purchased intangibles | - | - | 310 | 285 |
| Net premiums earned | - | - | 45,712 | 40,389 |
| Losses and loss expenses | - | - | 24,100 | 23,342 |
| Policy benefits | - | - | 3,628 | 1,492 |
| Policy acquisition costs | - | - | 8,259 | 7,392 |
| Administrative expenses | - | - | 4,007 | 3,395 |
| Underwriting income (loss) | - | - | 5,718 | 4,768 |
| Segment income (loss) | - | - | 11,181 | 8,151 |
| Interest expense | - | - | -672 | - |
| Net income | 10,622 | 9,640 | 9,015 | 5,313 |
| Net realized gains losses | 211 | 117 | -607 | -965 |
| Market risk benefit, change in fair value, gain (loss) | -288 | -140 | -307 | - |
| Accretion (amortization) of discounts and premiums, investments | 409 | 367 | 148 | -189 |
| Amortization of purchased intangibles | 301 | 323 | 310 | 285 |
| Equity in net income of subsidiaries and affiliates | 1,143 | 967 | 867 | 16 |
| Deferred income taxes | -330 | -96 | 1,124 | -132 |
| Unpaid losses and loss expenses | 2,706 | 4,567 | 3,470 | 4,222 |
| Unearned premiums | 2,098 | 1,805 | 1,377 | 1,477 |
| Future policy benefits | 2,186 | 1,841 | 848 | 464 |
| Insurance and reinsurance balances payable | 131 | -105 | -155 | 461 |
| Accounts payable, accrued expenses, and other liabilities | 53 | 342 | -735 | 223 |
| Income taxes | -160 | 69 | 128 | -149 |
| Insurance and reinsurance balances receivable | 1,167 | 1,278 | 1,072 | 696 |
| Reinsurance recoverable | 169 | 30 | 498 | 1,776 |
| Deferred policy acquisition costs | 1,566 | 1,429 | 1,100 | 328 |
| Net sales of investments by consolidated investment products | -1,090 | 278 | 450 | - |
| Other | -16 | -1,374 | -1,819 | -477 |
| Net cash provided by (used) in operating activities, total | 12,816 | 16,182 | 12,632 | 11,243 |
| Purchases of fixed maturities available-for-sale | 34,157 | 33,759 | 28,672 | 27,844 |
| Purchases of fixed maturities held-to-maturity | 0 | 0 | 208 | 618 |
| Purchases of equity securities | 2,799 | 4,333 | 1,395 | 895 |
| Sales of fixed maturities available-for-sale | 12,231 | 12,815 | 14,593 | 16,855 |
| Sales of equity securities | 2,807 | 2,996 | 1,084 | 4,615 |
| Maturities and redemptions of fixed maturities available-for-sale | 12,675 | 10,810 | 7,026 | 9,415 |
| Maturities and redemptions of fixed maturities held-to-maturity | 0 | 0 | 708 | 1,712 |
| Net change in short-term investments | -462 | 763 | -1,169 | 1,452 |
| Net derivative instruments settlements | 185 | 93 | 153 | 84 |
| Private equity contributions | 3,014 | 1,070 | 2,024 | 2,649 |
| Private equity distributions | 1,721 | 1,397 | 1,164 | 1,017 |
| Acquisition of subsidiaries (net of cash acquired of 32, nil, and 560) | 289 | 538 | 34 | 4,982 |
| Payment, including deposit, for huatai group interest | - | - | - | 184 |
| Cash and cash equivalents increase (decrease) due to consolidation and deconsolidation of investment products | 0 | -27 | 17 | - |
| Other | 712 | 1,412 | 889 | 560 |
| Cash provided by (used in) investing activity, including discontinued operation | -11,260 | -13,923 | -7,648 | -5,654 |
| Dividends paid on common shares | 1,505 | 1,436 | 1,394 | 1,375 |
| Common shares repurchased | 3,694 | 1,801 | 2,411 | 2,894 |
| Proceeds from issuance of long-term debt | 2,424 | 2,408 | 0 | 0 |
| Repayments of long-term debt | 800 | 1,437 | 475 | 1,000 |
| Proceeds from share-based compensation plans | 327 | 356 | 212 | 264 |
| Policyholder contract deposits | 853 | 1,024 | 645 | 496 |
| Policyholder contract withdrawals | 594 | 709 | 458 | 519 |
| Third-party capital invested into consolidated investment products | 2,556 | 1,614 | 126 | - |
| Third-party capital distributed by consolidated investment products | 1,753 | 1,621 | 745 | - |
| Proceeds from issuance of repurchase agreements | 6,297 | 4,505 | 4,984 | 4,510 |
| Repayment of repurchase agreements | 5,693 | 4,822 | 4,728 | 4,508 |
| Tax withholding payments for share-based compensation plans | -268 | -262 | -245 | -101 |
| Net cash flows (used for) from financing activities | -1,850 | -2,181 | -4,489 | -5,127 |
| Effect of foreign currency rate changes on cash and restricted cash | 215 | -150 | -1 | -146 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect | -79 | -72 | 494 | 316 |
| Cash and restricted cash - beginning of year | 2,549 | 2,621 | 2,127 | 1,811 |
| Cash and restricted cash - end of year | 2,470 | 2,549 | 2,621 | 2,127 |
Chubb Ltd (CB)
Chubb Ltd (CB)